California State Teachers Retirement System Sells 8,406 Shares of Supernus Pharmaceuticals, Inc. (SUPN)

California State Teachers Retirement System decreased its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 9.1% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 83,974 shares of the specialty pharmaceutical company’s stock after selling 8,406 shares during the quarter. California State Teachers Retirement System owned 0.17% of Supernus Pharmaceuticals worth $3,619,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Meeder Asset Management Inc. increased its position in shares of Supernus Pharmaceuticals by 3,455.2% in the second quarter. Meeder Asset Management Inc. now owns 2,382 shares of the specialty pharmaceutical company’s stock valued at $103,000 after buying an additional 2,315 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Supernus Pharmaceuticals by 278.2% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,018 shares of the specialty pharmaceutical company’s stock valued at $130,000 after buying an additional 2,220 shares in the last quarter. Riverhead Capital Management LLC increased its position in shares of Supernus Pharmaceuticals by 91.4% during the second quarter. Riverhead Capital Management LLC now owns 3,062 shares of the specialty pharmaceutical company’s stock worth $132,000 after purchasing an additional 1,462 shares in the last quarter. Advisor Group Inc. increased its position in shares of Supernus Pharmaceuticals by 13.7% during the second quarter. Advisor Group Inc. now owns 3,395 shares of the specialty pharmaceutical company’s stock worth $145,000 after purchasing an additional 410 shares in the last quarter. Finally, Victory Capital Management Inc. increased its position in shares of Supernus Pharmaceuticals by 17.7% during the second quarter. Victory Capital Management Inc. now owns 3,441 shares of the specialty pharmaceutical company’s stock worth $148,000 after purchasing an additional 517 shares in the last quarter. 96.45% of the stock is owned by institutional investors.

Supernus Pharmaceuticals, Inc. (SUPN) traded down $0.35 during trading hours on Wednesday, reaching $36.85. The company had a trading volume of 17,406 shares, compared to its average volume of 622,472. The stock has a market cap of $1,937.71, a P/E ratio of 35.66, a PEG ratio of 1.60 and a beta of 1.30. Supernus Pharmaceuticals, Inc. has a 12-month low of $20.55 and a 12-month high of $50.04.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.02. Supernus Pharmaceuticals had a return on equity of 26.37% and a net margin of 20.98%. The company had revenue of $80.40 million during the quarter, compared to analysts’ expectations of $78.74 million. The firm’s revenue was up 41.5% compared to the same quarter last year. research analysts expect that Supernus Pharmaceuticals, Inc. will post 1.07 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This story was first posted by Week Herald and is the property of of Week Herald. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://weekherald.com/2017/11/15/supernus-pharmaceuticals-inc-supn-shares-sold-by-california-state-teachers-retirement-system.html.

Several analysts have issued reports on SUPN shares. Stifel Nicolaus lowered Supernus Pharmaceuticals from a “buy” rating to a “hold” rating and set a $47.00 price target on the stock. in a research note on Tuesday, September 19th. They noted that the move was a valuation call. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $41.00 price target on shares of Supernus Pharmaceuticals in a research note on Tuesday, September 26th. FBR & Co started coverage on Supernus Pharmaceuticals in a research note on Thursday, October 19th. They set a “buy” rating and a $53.00 target price on the stock. Zacks Investment Research raised Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $47.00 target price on the stock in a research note on Wednesday, November 8th. Finally, BidaskClub raised Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, August 17th. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $49.60.

In other news, SVP Padmanabh P. Bhatt sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, September 8th. The stock was sold at an average price of $49.86, for a total value of $249,300.00. Following the completion of the sale, the senior vice president now directly owns 12,500 shares of the company’s stock, valued at approximately $623,250. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Stefan K.F. Schwabe sold 95,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $46.59, for a total value of $4,426,050.00. The disclosure for this sale can be found here. Insiders have sold a total of 150,000 shares of company stock valued at $7,055,350 over the last ninety days. 6.70% of the stock is owned by insiders.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply